If you have any questions for next week's webinar guest speakers (Atlantic Lithium, Cora Gold and Valirx), please submit here.

Less Ads, More Data, More Tools Register for FREE

UPDATE 1-Sanofi raises outlook after strong Q2 numbers

Mon, 29th Jul 2019 07:18

* Sees EPS growth of 5%, vs earlier 3-5% target

* Surge in Dupixent revenue

* Writedown of Bioverativ deal after weak Eloctate sales

* Shares up more than 2% (Adds share price, comment)

By Matthias Blamont

PARIS, July 29 (Reuters) - Sanofi has raised its 2019 outlook on the back of strong second-quarter results, which benefited from double-digit growth at the French drugmaker's vaccines and rare diseases businesses.

The company said on Monday it was now aiming for earnings per share growth of around 5% compared to an earlier target range of 3-5%.

The positive outlook boosted Sanofi's shares by 2.4% to 77.79 euros in early trading.

"Business EPS outlook is raised to the top-end, but suggests only minor potential upgrades to consensus, at most, in our view," wrote Peter Welford, an analyst at brokerage Jefferies.

Sanofi is betting on strong uptake of its drug Dupixent, which is used to treat a number of diseases. Dupixent was initially prescribed for atopic dermatitis and later approved for asthma and chronic rhinosinusitis.

Sales of Dupixent, developed with U.S firm Regeneron , rose 168% at constant exchange rates in the second quarter to 496 million euros ($551.80 million).

So far, the medicine has been made available in 28 countries and 18 launches are to take place by year-end.

Sanofi hopes Dupixent's strong sales prospects and other drugs at its rare diseases business Genzyme, along with those of vaccines and other upcoming products, will continue to offset weakness of the group's diabetes unit.

Diabetes sales in the second quarter were down 7%, hit again by pricing pressure on its patent-expired Lantus insulin.

WRITEDOWN

Second-quarter net income rose 4.9% at constant exchange rates to 1.64 billion euros while sales were up 3.9% to 8.63 billion euros.

Sanofi booked an 1.8 billion euros impairment charge in the quarter related to haemophilia product Eloctate, after lower sales in the U.S. and a revision of sales projections.

Eloctate's revenue fell 11%, a result of direct competition from Roche's Hemlibra, a newcomer in the market.

"It is a non-cash event of course but it is clear that the competition from Hemlibra was a surprise to everyone and it is indeed putting pressure," Sanofi chief financial officer Jean-Baptiste de Chatillon told reporters.

Eloctate was developed by U.S. haemophilia specialist Bioverativ, which Sanofi bought last year for $11.6 billion.

($1 = 0.8988 euros) (Reporting by Matthias Blamont; Editing by Sudip Kar-Gupta and Jane Merriman)

More News

UPDATE 1-Motor racing-Hamilton casts doubt on Kingspan branding remaining on car

(Adds Wolff comments)By Alan BaldwinDec 4 (Reuters) - Formula One world champion Lewis Hamilton cast doubt on Saturday on whether branding for a company linked to the 2017 Grenfell Tower fire would stay on his Mercedes race car amid a backlash in Bri...

Today 22:04

Motor racing-Hamilton casts doubt on Kingspan branding remaining on car

By Alan BaldwinDec 4 (Reuters) - Formula One world champion Lewis Hamilton cast doubt on Saturday on whether branding for a company linked to the 2017 Grenfell Tower fire would stay on his Mercedes race car amid a backlash in Britain and calls for hi...

Today 20:17

UPDATE 1-Britain tightens testing for inbound travellers, adds Nigeria to red list

(Adds quote, detail, context)LONDON, Dec 4 (Reuters) - Britain will require all inbound travellers to take a pre-departure COVID-19 test, and arrivals from Nigeria will have to quarantine in hotels to slow the spread of the Omicron variant, health...

Today 18:36

REUTERS NEXT-Omicron variant likely to usher growth downgrades -IMF's Georgieva

(Adds comment on climate change)By Andrea ShalalWASHINGTON, Dec 3 (Reuters) - Global economic growth projections from the International Monetary Fund will likely be downgraded due to the emergence of the Omicron variant of the coronavirus, IMF Man...

3 Dec 21 22:54

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.